NCT00860340已完成不适用
Hemodynamic Effects of Spironolactone in Patients With Heart Failure
University of Toledo Health Science Campus1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2003年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Echocardiogram
研究概览
简要总结
To determine if the beneficial effect of spironolactone in patients with congestive heart failure is in part due to its intrinsic inotropic action.
Randomized, two group placebo controlled, single blind study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •21 - 80 years
- •Serum creatinine < 2 mg/dL
- •Serum potassium 2.7 - 4.5 mg/dL measured within past 4 weeks
排除标准
- •Less than 21 years
- •Pregnancy
研究组 & 干预措施
1
Experimental
Study patient will take 100mg tablet of Spironolactone
干预措施: Spironolactone (Drug)
结局指标
主要结局
Echocardiogram
时间窗: 3 measurements 15 minutes apart before drug and 15 minutes for 2 hours after drug
Measure of Kidney function and potassium levels
时间窗: This will be taken before drug, two hours after and the following day
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
3 期
Spironolactone in the Treatment of Heart FailureNCT04727073Charite University, Berlin, Germany743
已完成
2 期
Spironolactone in Adult Congenital Heart DiseaseEndomyocardial FibrosisHeart FailureCongenital Heart DiseaseNCT01069510Oregon Health and Science University40
已完成
4 期
Antiarrhythmic Effects of Spironolactone in Patients With ICDsVentricular ArrhythmiasNCT04495712VA Office of Research and Development90
撤回
4 期
Spironolactone to Improve Apnea and Cardiovascular Markers in Obstructive Sleep Apnea PatientsObstructive Sleep ApneaNCT04205136University of Michigan
招募中
3 期
SPIRonolactone In the Treatment of Heart Failure - A double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone compared to placebo on the composite endpoint of recurrent heart failure hospitalizations and cardiovascular death in patients with heart failure with mid- range or preserved ejection fractioHeart failure with preserved or mid-range ejection fractionHFmrEF and HFpEF10019280NL-OMON54576Charité Universitätsmedizin Berlin100